LC
PTGX icon

Lindbrook Capital’s Protagonist Therapeutics PTGX Stock Holding History

Lindbrook Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.92K Buy
143
+77
+117% +$3.23K ﹤0.01% 1814
2024
Q4 		$2.55K Sell
66
-10
-13% -$436 ﹤0.01% 2230
2024
Q3 		$3.42K Buy
76
+27
+55% +$1.09K ﹤0.01% 2165
2024
Q2 		$1.7K Sell
49
-124
-72% -$3.63K ﹤0.01% 2395
2024
Q1 		$5K Buy
+173
New +$4.71K ﹤0.01% 1890
2022
Q3 		– Sell
-26
Closed – – 2857
2022
Q2 		$0 Buy
+26
New +$314 ﹤0.01% 2712
2021
Q4 		– Sell
-2,450
Closed -$43K – 2183
2021
Q3 		$43K Buy
2,450
+2,000
+444% +$85.3K 0.01% 482
2021
Q2 		$20K Sell
450
-2,750
-86% -$90.8K ﹤0.01% 784
2021
Q1 		$83K Buy
3,200
+2,000
+167% +$50.6K 0.02% 309
2020
Q4 		$24K Buy
1,200
+1,000
+500% +$21.5K 0.01% 621
2020
Q3 		$4K Hold
200
– – ﹤0.01% 1196
2020
Q2 		$4K Sell
200
-1,300
-87% -$16.3K ﹤0.01% 1192
2020
Q1 		$11K Buy
+1,500
New +$11.2K ﹤0.01% 731

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's PTGX Position: Q1 2025 in Review

Lindbrook Capital increased its Protagonist Therapeutics (PTGX) stake by 117% in Q1 2025, buying an estimated $3.23K and bringing the position to 143 shares worth $6.92K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Lindbrook Capital first reported a position in PTGX in Q1 2020 and has held it in 13 quarters since. The position peaked at $83K in Q1 2021. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Lindbrook Capital held 143 shares of Protagonist Therapeutics worth $6.92K as of Q1 2025.
  • Lindbrook Capital bought 77 Protagonist Therapeutics shares in Q1 2025, an estimated $3.23K.
  • Protagonist Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1814 holding.
  • Lindbrook Capital first reported a position in Protagonist Therapeutics in Q1 2020 and has held it in 13 quarters since.
  • Lindbrook Capital's Protagonist Therapeutics position peaked at $83K in Q1 2021.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.